Zoetis Inc (NYSE:ZTS) has been assigned a consensus recommendation of “Buy” from the nineteen ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $90.53.
Several equities analysts recently commented on ZTS shares. Cantor Fitzgerald restated a “buy” rating and set a $98.00 target price on shares of Zoetis in a research report on Wednesday, May 16th. Craig Hallum restated a “buy” rating and set a $94.00 target price (up from $87.00) on shares of Zoetis in a research report on Wednesday, April 25th. Bank of America boosted their target price on Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Jefferies Financial Group set a $96.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Friday, July 13th. Finally, Citigroup restated a “buy” rating and set a $98.00 target price (up from $85.00) on shares of Zoetis in a research report on Thursday, April 19th.
In other news, insider Kristin C. Peck sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $86.22, for a total value of $431,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Roxanne Lagano sold 2,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $84.76, for a total value of $169,520.00. Following the completion of the transaction, the insider now owns 22,023 shares of the company’s stock, valued at $1,866,669.48. The disclosure for this sale can be found here. Insiders sold a total of 197,099 shares of company stock valued at $17,978,939 over the last quarter. Company insiders own 0.35% of the company’s stock.
Shares of NYSE ZTS traded up $0.69 during mid-day trading on Thursday, hitting $91.54. The company had a trading volume of 2,462,400 shares, compared to its average volume of 2,656,778. The stock has a market cap of $44.18 billion, a PE ratio of 37.91, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. Zoetis has a 1 year low of $60.44 and a 1 year high of $93.67. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06. The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.53 earnings per share. sell-side analysts predict that Zoetis will post 3.07 EPS for the current year.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Fundamental Analysis
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.